Shared on24 Sep 25Fair value Decreased 2.72%
Globus Medical’s price target was revised downward as analysts cited muted year-over-year performance in the Enabling Technology segment and less-than-expected robotic sales growth, despite an EPS beat and quarter-to-quarter recovery, resulting in a new fair value of $80.30. Analyst Commentary Q2 sales were in line with the company's pre-announcement.
Shared on30 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Decreased 0.63%
AnalystConsensusTarget has increased revenue growth from 6.7% to 7.6%.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 1.26%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Decreased 0.63%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on10 Mar 25Fair value Increased 16%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.